首页> 外文OA文献 >Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes
【2h】

Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes

机译:口服人胰岛素或猪胰岛素与霍乱毒素(CTB)B亚基的偶联克服了关键的抗原差异,可预防I型糖尿病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Our earlier investigations have demonstrated a critical difference in the efficacy of orally administered porcine compared to human or mouse insulin (no effect) in preventing type I diabetes in two distinct experimental models. Based on these findings one has to assume that certain insulins might not be suitable for the induction of oral ‘tolerance’/bystander suppression, which might be one cause for recent failures in human oral antigen trials. Here we demonstrate that coupling to the non-toxic subunit of cholera toxin (CTB) can abolish these differences in efficacy between human and porcine insulin. As expected, an added benefit was the much smaller oral antigen dose required to induce CD4+ insulin-B specific regulatory cells that bystander-suppress autoaggressive responses. Mechanistically we found that uptake or transport of insulin–CTB conjugates in the gut occurs at least partially via binding to GM-1, which would explain the enhanced clinical efficacy. Both B chains bound well to major histocompatibility complex (MHC) class II, indicating comparable immunological potential once uptake and processing has occurred. Thus, our findings delineate a pathway to overcome issues in oral antigen choice for prevention of type I diabetes.
机译:我们的较早研究表明,在两个不同的实验模型中,与人或小鼠胰岛素相比,口服猪的功效与人或小鼠的胰岛素相比有关键差异(无作用)。基于这些发现,人们必须假设某些胰岛素可能不适合诱导口服“耐受” /旁观者抑制,这可能是人类口服抗原试验近期失败的原因之一。在这里,我们证明,与霍乱毒素(CTB)的无毒亚基偶联可以消除人胰岛素和猪胰岛素之间的功效差异。如预期的那样,另一个好处是诱导旁观者抑制自激反应的CD4 +胰岛素B特异性调节细胞所需的口服抗原剂量小得多。从机理上讲,我们发现肠道中胰岛素-CTB偶联物的吸收或转运至少部分通过与GM-1结合而发生,这可以解释其临床疗效的提高。两条B链均与II类主要组织相容性复合物(MHC)结合良好,表明一旦发生摄取和加工,其免疫学潜力相当。因此,我们的发现勾勒出一种途径,以克服预防I型糖尿病的口服抗原选择问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号